Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study

BOURKE, Liam, STEVENSON, Richard, TURNER, Rebecca, HOOPER, R, SASIENI, P, GREASLEY, Rosa, MORRISSEY, D, LOOSEMOORE, Mike, FISHER, A, PAYNE, H, TAYLOR, S.J.C and ROSARIO, D.J (2018). Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study. Scientific Reports, 8 (1), p. 8374. [Article]

Documents
21257:465147
[thumbnail of Bourke-ExerciseTrainingAsANovelPrimaryTreatment(AM).pdf]
Preview
PDF
Bourke-ExerciseTrainingAsANovelPrimaryTreatment(AM).pdf - Accepted Version
Available under License Creative Commons Attribution.

Download (645kB) | Preview
21257:465148
[thumbnail of Appendix 1]
Preview
PDF (Appendix 1)
Bourke-ExerciseTrainingAsANovelPrimaryTreatment(App1).pdf - Supplemental Material
Available under License Creative Commons Attribution.

Download (489kB) | Preview
21257:465149
[thumbnail of Appendix 2]
Preview
PDF (Appendix 2)
Bourke-ExerciseTrainingAsANovelPrimaryTreatment(App2).pdf - Supplemental Material
Available under License Creative Commons Attribution.

Download (452kB) | Preview
21257:465150
[thumbnail of Appendix 3]
Preview
PDF (Appendix 3)
Bourke-ExerciseTrainingAsANovelPrimaryTreatment(App3).pdf - Supplemental Material
Available under License Creative Commons Attribution.

Download (331kB) | Preview
21257:465020
[thumbnail of Fig 1]
Preview
PDF (Fig 1)
Figure 1.pdf - Supplemental Material
Available under License Creative Commons Attribution.

Download (104kB) | Preview
21257:465021
[thumbnail of Fig 2]
Preview
PDF (Fig 2)
Figure 2.pdf - Supplemental Material
Available under License Creative Commons Attribution.

Download (84kB) | Preview
Abstract
Alternative management strategies for localised prostate cancer are required to reduce morbidity and overtreatment. The aim of this study was to evaluate the feasibility, safety and acceptability of exercise training (ET) with behavioural support as a primary therapy for low/intermediate risk localised prostate cancer. Men with low/intermediate-risk prostate cancer were randomised to 12 months of ET or usual care with physical activity advice (UCwA) in a multi-site open label RCT. Feasibility included acceptability, recruitment, retention, adherence, adverse events and disease progression. Secondary outcomes included quality of life and cardiovascular health indices. Of the 50 men randomised to ET (n=25) or UCwA (n=25), 92% (n=46) completed 12 month assessments. Three men progressed to invasive therapy (two in UCwA). In the ET group, men completed mean: 140 mins per week for 12 months (95% CI 129,152mins) (94% of target dose) at 75% Hrmax. Men in the ET group demonstrated improved body mass (mean reduction: 2.0 kg; 95% CI -2.9,-1.1), reduced systolic (mean: 13 mmHg; 95% CI 7,19) and diastolic blood pressure (mean:8 mmHg; 95% CI 5,12) and improved quality of life (EQ5D mean:13 points; 95% CI 7,18). There were no serious adverse events. ET in men with low/intermediate risk prostate cancer is feasible and acceptable with a low progression rate to radical treatment. Early signals on clinically relevant markers were found which warrant further investigation.
More Information
Statistics

Downloads

Downloads per month over past year

Metrics

Altmetric Badge

Dimensions Badge

Share
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Actions (login required)

View Item View Item